Skip to content
TrialMatch
Sign up
Recruiting

VR Pupillometry in Cognitive Impairment

Create a profile to match View the full record on ClinicalTrials.gov

About this study

With disease-modifying therapies emerging for dementia and related conditions, identifying cognitive decline as early as possible is increasingly important. This prospective, single-center, repeated-measures study evaluates whether VR-based eye-tracking pupillometry can provide a practical, non-invasive biomarker of cognitive impairment and its progression over time. Pupil responses are linked to brain arousal systems relevant to cognitive dysfunction, including the locus coeruleus, which is affected early in Alzheimer's disease. Adults aged 18-80 years will be assigned to one of four cohorts (n=35 per cohort): i) Alzheimer's disease (supported by CSF biomarkers), ii) mild cognitive impairment (MCI) without Alzheimer's Disease, iii) depressive disorder with cognitive impairment, iv) healthy controls. Participants will undergo initial assessments at baseline and follow-up visits after 3 and 6 months. At each visit, pupil responses and behavioral metrics are recorded during a pupillary light reflex paradigm, a resting-state fixation block, a working-memory task (N-back), and a reward task. Pupillometric and behavioral metrics will be compared across cohorts and related to routine neuropsychological measures (MoCA, CERAD) and available clinical biomarkers (CSF markers; blood biomarkers). The primary objective is to determine whether task-evoked pupil response profiles sensitively quantify cognitive impairment, differ between cohorts, and track change over time. The long-term goal is to validate an easy-to-use, outpatient-compatible assessment to support objective characterization and monitoring of cognitive disorders.

Condition
Alzheimer s Disease, Major Depressive Disorder (MDD), Mild Cognitive Impairment, Dementia
Sponsor
Max-Planck-Institute of Psychiatry

Who can join

Age
18 to 80 years
Sex
All sexes
Healthy volunteers
Accepted

Inclusion 7

  • Minimum age: 18 years
  • Maximum age: 80 years
  • Study condition: Alzheimer s Disease, Major Depressive Disorder (MDD), Mild Cognitive Impairment, Dementia
  • Written informed consent.
  • Age 18-80 years.
  • Ability to read and understand German.
  • For patient cohorts: suspected or confirmed diagnosis of AD/MCI/depressive disorder with cognitive impairment according to clinical assessment and routine documentation.

Exclusion 9

  • Acute suicidality (e.g. BDI suicidality item \> 1).
  • Change of psychotropic medication within the last 4 weeks.
  • Lifetime psychotic disorder (ICD-10 F20-29).
  • Lack of capacity to consent.
  • Lifetime bipolar disorder (ICD-10 F31).
  • Acute substance abuse or harmful use of alcohol or other psychoactive substances.
  • Parkinson's syndrome (ICD-10 G20).
  • Multiple sclerosis (ICD-10 G35).
  • Stroke within the last 12 months.

Where

1 site, 1 recruiting

Max Planck Institute of Psychiatry

München, Bavaria, Germany

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.